Rigetti Stock Rises on CHIPS Act LOI
Rigetti stock climbed after a letter of intent for up to $100 million in CHIPS Act support, spurring a rally in quantum computing shares.
KEY TAKEAWAYS
- LOI contemplates up to $100 million in CHIPS Act support across three years.
- The LOI is non-binding; the final mix of grants, loans or equity determines dilution risk.
- The announcement boosted quantum computing shares while leaving execution and cash risks unresolved.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Rigetti stock jumped on May 21, 2026, after the company said it signed a letter of intent with the U.S. Department of Commerce that contemplates up to $100 million in CHIPS Act support over three years, a development that helped lift other quantum computing shares.
CHIPS LOI Details and Funding Structure
Rigetti Computing, Inc. (NASDAQ: RGTI) develops superconducting quantum processors and cloud quantum-computing services. The company said in a press release it signed a letter of intent (LOI) with the U.S. Department of Commerce under the CHIPS and Science Act to support superconducting quantum research and development. The LOI is a preliminary, non-binding framework; any funding would depend on due diligence, negotiation of definitive agreements, and federal approvals.
Secondary reports indicate the support could take the form of grants, loans, or an equity stake. An equity component would introduce dilution risk for existing shareholders. Projects funded under CHIPS program rules may also face domestic-content, national-security, and export-control requirements that could affect deployment.
Market Reaction and Company Fundamentals
The LOI announcement coincided with a sharp rally in Rigetti and other quantum computing stocks on May 21–22, 2026, as market participants linked the move to increased government funding for quantum technologies. Analysts described the LOI as a credibility boost for Rigetti’s superconducting hardware roadmap while noting the company’s modest revenue, substantial quarterly losses, and early-stage commercialization.
One market report recorded a consensus "Moderate Buy" rating on the shares with an average price target of $29.18. For investors, the key issue is the LOI’s structure: because it is preliminary and the final mix of grants, loans, or equity is unclear, the impact on valuation depends on whether the funding is dilutive and on milestone and compliance terms. A grant-like award would avoid dilution but could impose program conditions. An equity-linked instrument would provide capital while expanding the share base and potentially altering governance.
The LOI offers a conditional path to additional capital and accelerated R&D but does not eliminate execution risks tied to long commercialization timelines and the capital intensity of scaling quantum hardware.
